| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6878721 | NOVARTIS | Beta2-adrenoceptor agonists |
Feb, 2025
(1 year, 4 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8479730 | NOVARTIS | Inhaler device |
Oct, 2028
(5 years from now) | |
| US8182838 | NOVARTIS | Dry powder composition comprising co-jet milled particles for pulmonary inhalation |
Oct, 2028
(5 years from now) | |
Utibron is owned by Novartis.
Utibron contains Glycopyrrolate; Indacaterol Maleate.
Utibron has a total of 3 drug patents out of which 0 drug patents have expired.
Utibron was authorised for market use on 29 October, 2015.
Utibron is available in powder;inhalation dosage forms.
Utibron can be used as long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd).
The generics of Utibron are possible to be released after 20 October, 2028.
Drugs and Companies using GLYCOPYRROLATE; INDACATEROL MALEATE ingredient
Market Authorisation Date: 29 October, 2015
Treatment: Long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (copd)
Dosage: POWDER;INHALATION
UTIBRON family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic